235 related articles for article (PubMed ID: 11560493)
1. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
Hammarström P; Jiang X; Deechongkit S; Kelly JW
Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
[TBL] [Abstract][Full Text] [Related]
2. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
[TBL] [Abstract][Full Text] [Related]
3. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
Lai Z; McCulloch J; Lashuel HA; Kelly JW
Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
5. The pathway by which the tetrameric protein transthyretin dissociates.
Foss TR; Wiseman RL; Kelly JW
Biochemistry; 2005 Nov; 44(47):15525-33. PubMed ID: 16300401
[TBL] [Abstract][Full Text] [Related]
6. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
9. Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding.
Miyata M; Sato T; Mizuguchi M; Nakamura T; Ikemizu S; Nabeshima Y; Susuki S; Suwa Y; Morioka H; Ando Y; Suico MA; Shuto T; Koga T; Yamagata Y; Kai H
Biochemistry; 2010 Jan; 49(1):114-23. PubMed ID: 19950966
[TBL] [Abstract][Full Text] [Related]
10. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
12. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
Sekijima Y; Dendle MA; Kelly JW
Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
[TBL] [Abstract][Full Text] [Related]
13. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
14. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
[TBL] [Abstract][Full Text] [Related]
15. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
17. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022
[TBL] [Abstract][Full Text] [Related]
19. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
20. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
